<p>Compass Therapeutics, Inc.（纳斯达克代码：CMPX - 获取免费报告）在周二的午盘交易中股价上涨了 4.5%。该股票最高交易价格为 5.39 美元，最后交易价格为 5.38 美元。午盘交易中大约交易了 1,662,732 股，较平均每日交易量 1,705,218 股下降了 2%。该股票此前收盘价为 5.15 美元。</p>
<p>获取 <strong>Compass Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>顶级 3 家高动量公司分析师仍然看好</li>
</ul>
<p>多位研究分析师对该股票发表了看法。JMP Securities 在 12 月 3 日的研究报告中将 Compass Therapeutics 的目标股价设定为 10.00 美元。Cantor Fitzgerald 在 12 月 3 日的研究报告中开始覆盖 Compass Therapeutics 的股票，并给予 “增持” 评级。Canaccord Genuity Group 在 12 月 3 日的研究报告中开始覆盖 Compass Therapeutics 的股票，给予 “买入” 评级和 10.00 美元的目标价格。Citizens Jmp 在 12 月 3 日的研究报告中开始覆盖 Compass Therapeutics，给予 “市场表现优于大盘” 评级和 10.00 美元的目标股价。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Compass Therapeutics 的 “卖出（d-）” 评级。一位分析师给予该股票 “强烈买入” 评级，十三位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 12.23 美元。</p>
<p><strong>阅读我们关于 CMPX 的最新研究报告</strong></p>
<h2>Compass Therapeutics 价格表现</h2>
<p>该公司的市值为 9.5689 亿美元，市盈率为-11.96，贝塔值为 1.44。该公司的 50 日移动平均线为 4.81 美元，200 日移动平均线为 3.78 美元。</p>
<p>Compass Therapeutics（纳斯达克代码：CMPX - 获取免费报告）最近在 11 月 5 日发布了季度财报。该公司报告每股收益为（0.08 美元），超出分析师共识预期的（0.14 美元）0.06 美元。整体来看，股票分析师预计 Compass Therapeutics, Inc.在当前财政年度将发布-0.36 美元的每股收益。</p>
<h2>对 Compass Therapeutics 的对冲基金观点</h2>
<p>机构投资者最近增持或减持了该公司的股份。Russell Investments Group Ltd.在第三季度将其在 Compass Therapeutics 的股份增加了 3,933.7%。Russell Investments Group Ltd.目前拥有该公司 7,785 股股票，价值 27,000 美元，此前在上个季度购买了 7,592 股。Apollon Wealth Management LLC 在第三季度购买了 Compass Therapeutics 的新股份，价值 35,000 美元。CIBC Bancorp USA Inc.在第三季度收购了 Compass Therapeutics 的新股份，价值 37,000 美元。Creative Planning 在第二季度购买了 Compass Therapeutics 的新头寸，价值 30,000 美元。最后，Victory Capital Management Inc.在第三季度增持了 Compass Therapeutics 的股份 20.6%。Victory Capital Management Inc.目前拥有该公司 12,652 股股票，价值 44,000 美元，此前在上个季度购买了 2,164 股。68.43% 的股票目前由机构投资者和对冲基金持有。</p>
<h2>Compass Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Compass Therapeutics, Inc 是一家临床阶段的生物技术公司，致力于新型免疫肿瘤疗法的发现和开发。公司总部位于马萨诸塞州剑桥，专注于工程化单克隆抗体候选药物，旨在增强 T 细胞介导的抗肿瘤反应。Compass 利用专有抗体平台识别和优化调节免疫检查点通路和肿瘤微环境的生物制剂。</p>
<p>该公司的主要项目包括 CTX-471，一种双特异性抗体，靶向 PD-1 和 PD-L1 检查点，以及 DSP107，一种 CD47-SIRPα通路调节剂，旨在破坏癌细胞上的 “别吃我” 信号。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Compass Therapeutics</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人只是不知道而已）</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将爆发</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Compass Therapeutics 吗？</h2>
<p>在你考虑 Compass Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Compass Therapeutics 并不在名单上。</p>
<p>虽然 Compass Therapeutics 目前在分析师中有适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CMPX

<p>Compass Therapeutics（纳斯达克代码：CMPX）股价在午盘交易中上涨 4.5%，至 5.38 美元，交易量约为 166 万股。分析师设定的目标价为 10.00 美元，评级范围从强烈买入到卖出。该公司报告每股收益为（0.08 美元），超出预期。机构投资者持有 68.43% 的股份。Compass Therapeutics 专注于开发免疫肿瘤疗法，主要项目针对 PD-1 和 CD47 通路</p>

<p>Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) shares rose 4.5% during mid-day trading on Tuesday . The stock traded as high as $5.39 and last traded at $5.38. Approximately 1,662,732 shares were traded during mid-day trading, a decline of 2% from the average daily volume of 1,705,218 shares. The stock had previously closed at $5.15.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc.（纳斯达克代码：CMPX - 获取免费报告）在周二的午盘交易中股价上涨了 4.5%。该股票最高交易价格为 5.39 美元，最后交易价格为 5.38 美元。午盘交易中大约交易了 1,662,732 股，较平均每日交易量 1,705,218 股下降了 2%。该股票此前收盘价为 5.15 美元。</p>
</div><p>Get <strong>Compass Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Compass Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Top 3 High-Momentum Companies Analysts Are Still Bullish On</li>
</ul>
<div class="lb-trans"><ul>
<li>顶级 3 家高动量公司分析师仍然看好</li>
</ul>
</div><p>A number of research analysts have weighed in on the stock. JMP Securities set a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. Cantor Fitzgerald began coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They issued an &#34;overweight&#34; rating on the stock. Canaccord Genuity Group started coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They issued a &#34;buy&#34; rating and a $10.00 target price for the company. Citizens Jmp began coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They issued a &#34;market outperform&#34; rating and a $10.00 price target on the stock. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $12.23.</p>
<div class="lb-trans"><p>多位研究分析师对该股票发表了看法。JMP Securities 在 12 月 3 日的研究报告中将 Compass Therapeutics 的目标股价设定为 10.00 美元。Cantor Fitzgerald 在 12 月 3 日的研究报告中开始覆盖 Compass Therapeutics 的股票，并给予 “增持” 评级。Canaccord Genuity Group 在 12 月 3 日的研究报告中开始覆盖 Compass Therapeutics 的股票，给予 “买入” 评级和 10.00 美元的目标价格。Citizens Jmp 在 12 月 3 日的研究报告中开始覆盖 Compass Therapeutics，给予 “市场表现优于大盘” 评级和 10.00 美元的目标股价。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Compass Therapeutics 的 “卖出（d-）” 评级。一位分析师给予该股票 “强烈买入” 评级，十三位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 12.23 美元。</p>
</div><p><strong>Read Our Latest Research Report on CMPX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CMPX 的最新研究报告</strong></p>
</div><h2>Compass Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Compass Therapeutics 价格表现</h2>
</div><p>The firm has a market cap of $956.89 million, a price-to-earnings ratio of -11.96 and a beta of 1.44. The business has a 50-day moving average of $4.81 and a 200-day moving average of $3.78.</p>
<div class="lb-trans"><p>该公司的市值为 9.5689 亿美元，市盈率为-11.96，贝塔值为 1.44。该公司的 50 日移动平均线为 4.81 美元，200 日移动平均线为 3.78 美元。</p>
</div><p>Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.06. As a group, equities analysts anticipate that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Compass Therapeutics（纳斯达克代码：CMPX - 获取免费报告）最近在 11 月 5 日发布了季度财报。该公司报告每股收益为（0.08 美元），超出分析师共识预期的（0.14 美元）0.06 美元。整体来看，股票分析师预计 Compass Therapeutics, Inc.在当前财政年度将发布-0.36 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Compass Therapeutics</h2>
<div class="lb-trans"><h2>对 Compass Therapeutics 的对冲基金观点</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its stake in shares of Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company's stock worth $27,000 after purchasing an additional 7,592 shares during the last quarter. Apollon Wealth Management LLC bought a new stake in Compass Therapeutics in the 3rd quarter valued at $35,000. CIBC Bancorp USA Inc. acquired a new stake in Compass Therapeutics during the 3rd quarter valued at $37,000. Creative Planning bought a new position in Compass Therapeutics during the second quarter worth $30,000. Finally, Victory Capital Management Inc. increased its holdings in shares of Compass Therapeutics by 20.6% in the third quarter. Victory Capital Management Inc. now owns 12,652 shares of the company's stock valued at $44,000 after purchasing an additional 2,164 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者最近增持或减持了该公司的股份。Russell Investments Group Ltd.在第三季度将其在 Compass Therapeutics 的股份增加了 3,933.7%。Russell Investments Group Ltd.目前拥有该公司 7,785 股股票，价值 27,000 美元，此前在上个季度购买了 7,592 股。Apollon Wealth Management LLC 在第三季度购买了 Compass Therapeutics 的新股份，价值 35,000 美元。CIBC Bancorp USA Inc.在第三季度收购了 Compass Therapeutics 的新股份，价值 37,000 美元。Creative Planning 在第二季度购买了 Compass Therapeutics 的新头寸，价值 30,000 美元。最后，Victory Capital Management Inc.在第三季度增持了 Compass Therapeutics 的股份 20.6%。Victory Capital Management Inc.目前拥有该公司 12,652 股股票，价值 44,000 美元，此前在上个季度购买了 2,164 股。68.43% 的股票目前由机构投资者和对冲基金持有。</p>
</div><h2>Compass Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Compass Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc 是一家临床阶段的生物技术公司，致力于新型免疫肿瘤疗法的发现和开发。公司总部位于马萨诸塞州剑桥，专注于工程化单克隆抗体候选药物，旨在增强 T 细胞介导的抗肿瘤反应。Compass 利用专有抗体平台识别和优化调节免疫检查点通路和肿瘤微环境的生物制剂。</p>
</div><p>The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.</p>
<div class="lb-trans"><p>该公司的主要项目包括 CTX-471，一种双特异性抗体，靶向 PD-1 和 PD-L1 检查点，以及 DSP107，一种 CD47-SIRPα通路调节剂，旨在破坏癌细胞上的 “别吃我” 信号。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Compass Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Compass Therapeutics</li>
<li>请勿删除，立即阅读</li>
<li>崩盘已经开始（大多数人只是不知道而已）</li>
<li>警报：在 2026 年 1 月之前抛售这 5 只股票！</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将爆发</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Compass Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Compass Therapeutics 吗？</h2>
</div><p>Before you consider Compass Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Compass Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Compass Therapeutics 并不在名单上。</p>
</div><p>While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Compass Therapeutics 目前在分析师中有适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Compass Therapeutics (NASDAQ:CMPX) 股价上涨 4.5% - 接下来会如何发展？